5-HT3 Receptor Antagonists in the Control of Cisplatin-lnduced Delayed Emesis

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 78-85

  Ossi, M ^a   Anderson, E ^a   Freeman, A ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cisplatin; Delayed emesis; Dexamethasone; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; PLACEBO; SEROTONIN ANTAGONIST;

ADULT; AGED; ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; NAUSEA;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; PLACEBOS; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0030171191     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227645     Document Type: Article

References (22)

1. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujadc-Lauraine E, Paule B, Paes D, Bons J: Comparison of the 5-hydroxytrypta-mine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dosc metociopramide in the control of cisplatin-induced emesis, N Engl J Med 1990;322:816-821.
2. Dc Mulder PHM, Seynaeve C, Vcrmorken JB, van Liessum PA, Mols-Jevdevic S, Lane All-man E, Beranek P, Verweij J: Ondansetron compared with high-dosc mctoclopramide in the prophylaxis of acute and delayed cisplatin-induced nausea and vomiting - A multiccntre randomised, double-blind crossover study, Ann Intern Med 1990:113:834-840.
3. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Werthcim MS, Kelsen DP: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin, J Clin Oncol 1985:3:1379- 1384.
4. Martin M: The severity and pattern of emesis following different cytotoxic agents, Oncology 1996:53(suppl l):26-31.
5. Morran C, Smith DC, Anderson DA, McArdle CS: Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of anticmetics, Br Med J 1979:1: 1323-1324.
6. Martin M, Diaz-Rubio E, Encinar JCB, Santa-maria JMR, Larriba GJL, Marote R, Fores MA: Tolcrability, toxicity and acceptance of adjuvant chemotherapy FAC (5-fluorouraciI, Adriamvcin and cyclophosphamide) in breast cancer, A study of consecutive patients, Neoplasia 1988:5:8-14.
7. Stewart A: Optimal control of cyclophospha-midc-induced cmesis, Oncology 1996:53 (suppl 1):32-38.
8. Verweij J, de Wit R, de Mulder PHM: Optimal control of acute cisplatin-induced emesis, Oncology 1996;53(suppl 1):56-64.
9. Du Bois A, Vacli W, Kiechle-Schwarz M, Cramcr-Giraud U, Meerpohl HG: Pathophysiology, severity, pattern and risk factors for car-boplatin-induced emesis, Oncology 1996:53 (suppl 1):46-50.
10. Italian Group for Antiemetic Research: Ondansetron + dexamethasone vs, metoclopram-ide + dexamethasone + diphenhydramine in the prevention of cisplatin-induced emesis, Lancet 1992;340:96-99.
11. Verweij J: Optimal anti-emetic therapy for cis-platin-induccd emesis, Glaxo Satellite Symp ECC07 1993, pp 37-41.
12. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cir-rincione C, Groshen S: Controlling delayed vomiting: Double-blind randomised trial comparing placebo, dexamethasone alone and mctoclopramide plus dcxamcthasone in patients receiving cisplatin, J Clin Oncol 1989:7:108-114.
13. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Sanli E, Penza O, Ballatori E, del Favero A: Prcdictivc factors of delayed emesis in cisplatin-treatcd patients and antiemetic activity and tolerabili-tv of metociopramide or dexamethasone, Am J Clin Oncol 1991:14:238-242.
14. Scheider M: Incidence of delayed cisplatin-induced emesis following acute anti-emetic prophylaxis with granisetron: A historical review, SmithKline Beecham Satellite Svnip 15th ICC, 1990.
15. Roila F, Bracarda S, Tonato M, et al: Ondansetron (GR38032) in the prophylaxis of acutc and delayed cisplatin-induced emesis, Clin Oncol 1990:2:268-272.
16. Kris MG, Tyson LB, Clark RA, Gralla RJ: Oral ondansetron for the control of delayed emesis after cisplatin, Report of phase II study and a review of completed trials to manage delayed emesis, Cancer 1992:70:1012-1016.
17. Smylh J: Delayed cmesis after high-dose cisplatin - The residual problem, SmithKline Bee-eham Satellite Symp ESMO 1992, p 24-26.
18. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hes-keth PJ: The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo, Semin Oncol 1992; 19(suppl 10):67-71.
19. Heron JF, Goedhals L, Jordaan JP, Cunningham J, Cedar E: Oral granisctron alone and in the combination with dexamethasone: A dou-blc-blind randomized comparison against high-dose metociopramide plus dcxamcthasone in prevention of cisplatin-induced emesis, Ann Oncol 1994:5:579-584.
20. Dc Mulder PHM: Delayed emesis: Is there a role for 5-HTj antagonists? SmithKline Beecham Satellite Symp ESMO, 1994, pp 26-31.
21. Roila F, Tonato M, Cognctti F, Cortesi E, Fa-valli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatri E, Del Favero A: Prevention of cisplatin-induced emesis: A double-blind multiccntre randomised crossoverstudy comparing ondansetron and ondansetron plus dexamethasone, J Clin Oncol 1991; 9:675-678.
22. Smyih JF, Coleman RE, Nicolson M, Gall-meier GM, Leonard RCF, Cornblect MA, Allan SG, Upadhyaya BK, Bruntsch U: Does dcxamcthasone enhance control of acutc cis-plat in-induced cmesis bv ondansetron? Br J Med 1991:303:1423-1426.